What Are Beta-Blockers?
Beta-blockers (beta-adrenergic receptor antagonists) are medications that block the effects of adrenaline (epinephrine) and noradrenaline on beta-adrenergic receptors in the heart, lungs, and blood vessels. They slow the heart rate, reduce the force of heart contractions, and lower blood pressure — making them useful for a wide range of cardiovascular and non-cardiovascular conditions.
Common [beta-blockers](/drug-classes/beta-blockers) include [metoprolol](/drugs/metoprolol) (Lopressor, Toprol-XL), carvedilol (Coreg), atenolol (Tenormin), bisoprolol (Zebeta), propranolol (Inderal), labetalol (Trandate), and nebivolol (Bystolic).
How Beta-Blockers Work
The sympathetic nervous system uses adrenaline and noradrenaline to activate beta-adrenergic receptors. There are three main types:
- Beta-1 receptors — Primarily in the heart; activation increases heart rate and contractility
- Beta-2 receptors — Primarily in the lungs and blood vessels; activation causes bronchodilation and vasodilation
- Beta-3 receptors — In fat tissue; activation promotes fat breakdown
Beta-blockers competitively block these receptors. By blocking beta-1 receptors in the heart, they reduce heart rate (negative chronotropy) and contractility (negative inotropy), which reduces cardiac workload and oxygen demand. This is beneficial in [heart failure](/conditions/heart-failure), angina, and arrhythmias.
Types of Beta-Blockers
| Type | Selectivity | Examples | Key Feature |
|---|---|---|---|
| Cardioselective (beta-1 selective) | Primarily beta-1 | Metoprolol, atenolol, bisoprolol, nebivolol | Less bronchospasm; preferred in asthma/COPD (with caution) |
| Non-selective | Beta-1 and beta-2 | Propranolol, nadolol, timolol | Also blocks beta-2 (lungs, vessels); more side effects |
| Alpha + beta blocking | Beta-1, beta-2, and alpha-1 | Carvedilol, labetalol | Additional vasodilation via alpha-1 blockade; preferred in HFrEF |
What Are Beta-Blockers Used For?
| Indication | Evidence | Preferred Agent |
|---|---|---|
| Heart failure with reduced EF (HFrEF) | MERIT-HF, COPERNICUS, CIBIS-II: 34–35% mortality reduction | Carvedilol, metoprolol succinate, bisoprolol |
| Post-myocardial infarction | Reduces reinfarction and mortality | Metoprolol, carvedilol |
| Hypertension | Effective; no longer first-line per JNC 8 (unless compelling indication) | Metoprolol, atenolol, bisoprolol |
| Atrial fibrillation (rate control) | Effective for ventricular rate control | Metoprolol, atenolol, bisoprolol |
| Angina pectoris | Reduces angina frequency and exercise-induced ischemia | Metoprolol, atenolol, propranolol |
| Migraine prevention | Propranolol: FDA-approved for migraine prophylaxis | Propranolol, metoprolol |
| Essential tremor | Propranolol: FDA-approved | Propranolol |
| Performance [anxiety](/conditions/anxiety) | Off-label; reduces sympathetic symptoms | Propranolol (low dose) |
| Hyperthyroidism (symptomatic) | Controls tachycardia and tremor while awaiting definitive therapy | Propranolol, atenolol |
Side Effects of Beta-Blockers
Common Side Effects
- Fatigue and exercise intolerance — Reduced maximum heart rate limits exercise capacity; most common complaint
- Bradycardia — Heart rate below 60 bpm; usually asymptomatic but can cause dizziness
- Cold extremities — Reduced peripheral blood flow; hands and feet may feel cold
- Sexual dysfunction — Erectile dysfunction in men; more common with non-selective agents
- Weight gain — Modest weight gain (1–2 kg) common, especially with non-selective agents
- Depression — Reported but causality is debated; more common with lipophilic agents (propranolol)
Serious Side Effects
- Bronchospasm — Beta-2 blockade in the lungs can trigger bronchoconstriction; non-selective agents are more dangerous in asthma/COPD. Cardioselective agents (metoprolol, bisoprolol) can be used cautiously in mild-moderate COPD but are contraindicated in severe asthma.
- Masking of hypoglycemia — Beta-blockers blunt the tachycardia that warns diabetic patients of low blood sugar. Sweating is preserved. Cardioselective agents are preferred in diabetic patients.
- Rebound [hypertension](/conditions/hypertension) and angina — Abrupt discontinuation can cause rebound tachycardia, hypertension, and angina (even myocardial infarction). Always taper gradually.
Important Contraindications
- Cardiogenic shock or decompensated heart failure
- Severe bradycardia (<50 bpm) or high-degree AV block (without pacemaker)
- Severe reactive airway disease (asthma) — non-selective agents
- Cocaine toxicity — beta-blockers can worsen coronary spasm in cocaine-induced chest pain
Metoprolol vs Carvedilol: The Key Comparison
For heart failure with reduced ejection fraction (HFrEF), three beta-blockers have proven mortality benefit: carvedilol, metoprolol succinate (extended-release), and bisoprolol. Carvedilol is the only one with combined alpha+beta blockade, which provides additional vasodilation. The COMET trial (2003) found carvedilol reduced all-cause mortality by 17% more than metoprolol tartrate (immediate-release) in HFrEF — though this comparison used the immediate-release form of metoprolol, which is less effective than the extended-release form. For most HFrEF patients, any of the three proven agents is appropriate.
Can You Stop Beta-Blockers Suddenly?
No. Abrupt discontinuation of beta-blockers can cause rebound tachycardia, severe hypertension, and worsening angina — and has been associated with myocardial infarction in patients with coronary artery disease. Beta-blockers should always be tapered gradually over 1–2 weeks when discontinuation is necessary. See our article on stopping beta-blockers safely for a detailed tapering guide.
Cost and Generic Availability
Most beta-blockers are available as generics at very low cost. Metoprolol succinate (extended-release) typically costs $10–$25/month. Carvedilol is $10–$20/month. Atenolol is $4–$10/month. See our metoprolol cost guide for current pricing.
References
- MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
- Packer M, et al. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med. 2001;344(22):1651-1658.
- Poole-Wilson PA, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet. 2003;362(9377):7-13.
Save up to 80% on this medication
Use a free RxGo discount card at 67,000+ pharmacies — no sign-up, no insurance needed.
About the Author
James Okafor, RPh, MBA
Registered Pharmacist & Health Economics Writer
James Okafor is a registered pharmacist with over 12 years of experience in retail and clinical pharmacy settings. He holds an MBA with a focus on healthcare management and specializes in translating complex drug pricing, formulary, and insurance coverage topics into clear, actionable guidance for patients. Before joining RxGuide, James worked as a clinical pharmacist at a regional hospital system and as a pharmacy benefits consultant for a national PBM. His writing focuses on cost transparency, generic alternatives, and helping patients navigate the U.S. prescription drug system.
View full profile on our Editorial Team page →Get the RxGo app — free prescription discounts on the go
Works at 67,000+ pharmacies · No membership needed